MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology (NYSE American: MAIA) announced that an abstract on its second-generation telomere-targeting THIO prodrugs has been accepted for poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain (October 23-25, 2024). The presentation will showcase preclinical studies of MAIA-2021-20 and MAIA-2022-12, lipid-conjugated compounds derived from THIO, belonging to a new class called telomere targeting divalent dinucleotides.
The studies evaluated these compounds' efficacy alone and in combination with immune checkpoint-blocking antibodies. Results demonstrated high efficacy, ability to overcome immunotherapy resistance, and marked activity in advanced tumors, showing tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma, and hepatocellular carcinoma. MAIA is actively working to advance these candidates toward clinical development.
MAIA Biotechnology (NYSE American: MAIA) ha annunciato che un abstract sui suoi prodrugs di seconda generazione a bersaglio dei telomeri, THIO, è stato accettato per la presentazione in poster al 36° Simposio EORTC-NCI-AACR sui Target Molecolari e le Terapie Antitumorali a Barcellona, Spagna (23-25 ottobre 2024). La presentazione metterà in evidenza studi preclinici su MAIA-2021-20 e MAIA-2022-12, composti coniugati a lipidi derivati da THIO, appartenenti a una nuova classe chiamata dinucleotidi divalenti a bersaglio del telomero.
Gli studi hanno valutato l'efficacia di questi composti sia da soli che in combinazione con anticorpi bloccanti dei checkpoint immunitari. I risultati hanno dimostrato un'alta efficacia, la capacità di superare la resistenza all'immunoterapia e una marcata attività nei tumori avanzati, mostrando inibizione della crescita tumorale in modelli preclinici di carcinoma polmonare, carcinoma colorettale, melanoma e carcinoma epatocellulare. MAIA sta attivamente lavorando per far avanzare questi candidati verso lo sviluppo clinico.
MAIA Biotechnology (NYSE American: MAIA) anunció que un resumen sobre sus prodrugs de segunda generación dirigidos a telómeros, THIO, ha sido aceptado para presentación en póster en el 36º Simposio EORTC-NCI-AACR sobre Objetivos Moleculares y Terapias contra el Cáncer en Barcelona, España (23-25 de octubre de 2024). La presentación mostrará estudios preclínicos sobre MAIA-2021-20 y MAIA-2022-12, compuestos conjugados a lípidos derivados de THIO, que pertenecen a una nueva clase llamada dinucleótidos divalentes dirigidos a telómeros.
Los estudios evaluaron la eficacia de estos compuestos solos y en combinación con anticuerpos que bloquean puntos de control inmunológicos. Los resultados demostraron una alta eficacia, la capacidad de superar la resistencia a la inmunoterapia y una actividad notable en tumores avanzados, mostrando inhibición del crecimiento tumoral en modelos preclínicos de cáncer de pulmón, carcinoma colorrectal, melanoma y carcinoma hepatocelular. MAIA está trabajando activamente para avanzar estos candidatos hacia el desarrollo clínico.
MAIA Biotechnology (NYSE American: MAIA)는 바르셀로나, 스페인에서 열리는 제36회 EORTC-NCI-AACR 분자 표적 및 암 치료 심포지엄(2024년 10월 23-25일)에서 두 번째 세대 텔로미어 타겟 THIO 전구약물에 대한 초록이 포스터 발표로 수락되었다고 발표했습니다. 이 발표는 MAIA-2021-20 및 MAIA-2022-12와 같은 THIO에서 유래한 지질 결합 화합물들에 대한 전임상 연구를 보여줄 것입니다. 이 화합물은 텔로미어를 타겟으로 한 새로운 클래스인 이가결합 이핵산에 속합니다.
연구에서는 이 화합물의 단독 효과와 면역관문 차단 항체와의 병용 효능을 평가했습니다. 결과는 높은 효능을 입증하며, 면역 요법 내성을 극복할 수 있는 능력과 고급 종양에 대한 현저한 활성을 보여주었고, 폐암, 결장 직장암, 흑색종 및 간세포암의 전임상 모델에서 종양 성장 억제를 보여주었습니다. MAIA는 이 후보 물질들을 임상 개발로 나아가도록 적극적으로 노력하고 있습니다.
MAIA Biotechnology (NYSE American: MAIA) a annoncé qu'un résumé concernant ses prodrugs de deuxième génération ciblant les télomères, THIO, a été accepté pour présentation sous forme de poster lors du 36ème Symposium EORTC-NCI-AACR sur les Cibles Moléculaires et les Thérapies contre le Cancer à Barcelone, Espagne (23-25 octobre 2024). La présentation mettra en avant des études précliniques sur MAIA-2021-20 et MAIA-2022-12, des composés conjugués à des lipides dérivés de THIO, appartenant à une nouvelle classe appelée dinucléotides divalents ciblant les télomères.
Les études ont évalué l'efficacité de ces composés seuls et en combinaison avec des anticorps bloquant les points de contrôle immunitaires. Les résultats ont démontré une forte efficacité, une capacité à surmonter la résistance à l'immunothérapie, et une activité marquée dans les tumeurs avancées, montrant une inhibition de la croissance tumorale dans des modèles précliniques de cancer du poumon, carcinome colorectal, mélanome et carcinome hépatocellulaire. MAIA travaille activement à faire progresser ces candidats vers le développement clinique.
MAIA Biotechnology (NYSE American: MAIA) gab bekannt, dass ein Abstract zu seinen zweiten Generation Telomer-zielenden THIO-Prodrugs für die Posterpräsentation beim 36. EORTC-NCI-AACR Symposium über Molekulare Ziele und Krebs-Therapeutika in Barcelona, Spanien (23.-25. Oktober 2024), akzeptiert wurde. Die Präsentation wird präklinische Studien zu MAIA-2021-20 und MAIA-2022-12, lipidgekoppelten Verbindungen die von THIO abstammen und zu einer neuen Klasse gehören, die Telomerziehlend di-valente Dinukleotide genannt wird, vorstellen.
Die Studien bewerteten die Wirksamkeit dieser Verbindungen sowohl alleine als auch in Kombination mit immuncheckpoint-blockierenden Antikörpern. Die Ergebnisse zeigten eine hohe Wirksamkeit, die Fähigkeit, Immuntherapie-Resistenz zu überwinden, und eine markante Aktivität in fortgeschrittenen Tumoren, wobei das Tumorwachstum in präklinischen Modellen von Lungenkrebs, kolorektalem Karzinom, Melanom und hepatozellulärem Karzinom gehemmt wurde. MAIA arbeitet aktiv daran, diese Kandidaten in die klinische Entwicklung voranzubringen.
- Acceptance of abstract for presentation at a major cancer therapeutics symposium
- Preclinical studies show high efficacy and ability to overcome immunotherapy resistance
- Demonstrated tumor growth inhibition in multiple cancer types
- Active progress towards clinical development of new drug candidates
- Three U.S. patent applications submitted for second-generation telomere targeting agents
- Drug candidates still in preclinical stage, not yet advanced to clinical trials
- MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials
MAIA will present the results of preclinical studies for its new THIO-based prodrugs, designated as MAIA-2021-20 and MAIA-2022-12, which are lipid-conjugated compounds derived from THIO. These second-generation compounds belong to a new chemical class of molecules called telomere targeting divalent dinucleotides. These preclinical studies were designed to evaluate the efficacy of the new molecules alone and in combination with or without immune checkpoint-blocking antibodies (anti-PD-L1).
MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D. commented, “Our presentation will demonstrate that treatment with each of the prodrugs studied was highly efficacious and was shown to overcome immunotherapy resistance. Our results have shown marked activity in advanced tumors and resulted in tumor growth inhibition in preclinical models of lung cancer, colorectal carcinoma, melanoma and hepatocellular carcinoma. We are actively working to advance these candidates toward clinical development.”
Presentation details:
Title: |
New Dual-Pharmacophore Dinucleotide Prodrugs as Potent Telomere Targeting Anticancer Molecules |
Abstract number: |
ENA24-0044 |
Session title: |
New Drugs |
Date and time: |
Wednesday, October 23, 2024, at noon CEST |
Presenting author: |
Ilgen Mender, Ph.D., Director of Biology Research, MAIA Biotechnology |
Poster access: |
MAIA’s poster will be available at maiabiotech.com/publications on October 23, 2024 |
MAIA has designed and evaluated more than 80 THIO-like compounds to date and has submitted three
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015282129/en/
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
Source: MAIA Biotechnology, Inc.
FAQ
What new drug candidates did MAIA Biotechnology (MAIA) announce for cancer treatment?
Where will MAIA Biotechnology (MAIA) present its research on new THIO prodrugs?
What results did MAIA Biotechnology (MAIA) report from preclinical studies of its new THIO prodrugs?
How many THIO-like compounds has MAIA Biotechnology (MAIA) designed and evaluated to date?
